CLIP Childhood Leukemia Investigation Prague Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Hematooncology University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Internal Medicine 4 Hematology University Hospital Hradec Kralove and Faculty of Medicine Charles University Hradec Kralove Czech Republic; Department of Military Internal Medicine and Hygiene Military Faculty of Medicine University of Defence Hradec Kralove Czech Republic

Institute of Hematology and Blood Transfusion Prague Czech Republic

Institute of Hematology and Blood Transfusion Prague Czech Republic; Institute of Clinical and Experimental Hematology 1st Faculty of Medicine Charles University Prague Czech Republic

Internal Hematology and Oncology Clinic Faculty Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Internal Hematology and Oncology Clinic Faculty Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic; Central European Institute of Technology Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. PubMed PMC

Gökbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood. 2015;126(23):680.

Gökbuget N, Arnold R, Böhme A, et al. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. Blood. 2007;110(11):12.

Šálek C, Folber F, Froňková E, et al. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol. 2016;96(3):276-284. PubMed

Šálek C, Hrabovský Š, Folber F, et al. Treatment of adult patients with acute lymphoblastic leukemia in the Czech Republic in the period 2007-2020. Klin Onkol. 2023;36(4):382-395. PubMed

van der Velden VHJ, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611. PubMed

Svaton M, Skotnicova A, Reznickova L, et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood. 2023;141(5):529-533. PubMed PMC

Kotrová M, Koopmann J, Trautmann H, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022;6(10):3006-3010. PubMed PMC

Šálek C, Folber F, Froňková E, et al. Low levels of minimal residual disease after induction chemotherapy for BCR‐ABL1‐ negative acute lymphoblastic leukaemia in adults are clinically relevant. Br J Haematol. 2022;196(3):706-710. PubMed

Gökbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24(1):337-348. PubMed

Stanulla M, Dagdan E, Zaliova M, et al. IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240-1249. PubMed

Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66. PubMed

Advani AS, Moseley A, O’Dwyer KM, et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574-1582. PubMed PMC

van Baalen E, Gradowska P, Bellido M, et al. Blinatumomab added to prephase and consolidation therapy in adult B-ALL: a comparison of the consecutive HOVON-100 and H-146 studies. Hemasphere. 2024;8(S1):30-31.

Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320-333. PubMed PMC